The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics, 2022Project Title: Clinical Development of PDM608, a Potential Neuroprotective and Anti-inflammatory Long-acting Biologic for Parkinson’s Disease
Study Rationale: Targeting neuroinflammation by increasing T regulatory cell numbers is a promising strategy for treating Parkinson’s disease. We propose a Phase 1 trial in non-PD volunteers for our...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Validating BMPs as Novel Drug Candidates for Parkinson’s Disease
Study Rationale: Neurotrophic factors are prime candidates for the development of disease-modifying therapies, based on their properties to restore and maintain the functional integrity of neurons...
-
Parkinson’s Pathway Molecular Data Analysis Program, 2022Evaluating a Microbial Biomarker in Blood Samples for Parkinson’s Disease
Study Rationale: Diagnosing Parkinson’s disease (PD) currently involves evaluation by movement disorder specialists and assessment based on physical examination and questionnaires. This approach is...
-
Research Grant, 2022Self-reported Perceptions and Self-reported Outcomes on Motor and Non-motor Symptoms in the Parkinson's Disease Continuum: A Systematic Review of Mixed Methods
Study Rationale: People are unique in the way they experience quality of life. Throughout the progression of Parkinson's disease, patients and their care partners have different perceptions of motor...
-
Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics, 2022Identification and Quantification of Parkinson’s Disease Progression Using Digital Measures from a Wrist-worn Wearable Device - a Retrospective Study
Study Rationale: The combination of digital measures and machine learning (ML) holds great promise for improving critical aspects of Parkinson’s disease (PD) care, practice and research. Earlier PD...
-
Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2023(Supplement) Testing the Neuroprotective Efficacy of Modulating the Lysosomal Gene Atp6v0a1
Study Rationale: The lysosome is a part of a cell involved in degrading and recycling proteins and other large molecules. Parkinson's disease (PD) is linked to lysosomal dysfunction. In this study, we...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.